Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
6
Bullish
5
Bearish
3
Neutral
6
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Bearish
3
Neutral
6
Bullish
5
Bearish
3
Neutral
6
Bullish
5
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Sakar Healthcare Limited is an India‑based integrated pharmaceutical manufacturer and CDMO offering API‑to‑FDF capabilities across oral solids, sterile injectables (liquids and lyophilised), oral liquids and oncology formulations, operating EU‑GMP and WHO‑GMP certified facilities and supplying global partners and own‑brand exports to 60+ countries.
Sakar has deliberately repositioned toward oncology as a value driver: the Bavla facility is EU‑GMP approved, vertically integrates API and finished dosage manufacturing, and currently lists 55 oncology molecules developed with 32 dossiers ready for launch and eleven marketing authorisations granted, signalling a step‑change in product complexity and margin profile.
Q3FY26 displayed a sharp operational inflection: consolidated revenue rose 62% YoY to INR 70.34 crore, EBITDA grew 58% to INR 18.59 crore with 26% margins, and PAT more than doubled to INR 10.25 crore, reflecting improved mix, higher own‑brand exports and early commercialisation of oncology dossiers contributing to near‑term profitability expansion.
Commercial traction is supported by deep industry partnerships and technology transfers: Sakar disclosed inclusion as a manufacturing source for Accord/Intas Imatinib supplies, ten tech‑transfer products in process, longstanding client relationships with major Indian multinationals and a shift to own‑brand exports now contributing roughly 70% of revenues, improving margin resilience.
Sakar emphasizes sustainable process technology and backward integration: investments in flow chemistry, green chemistry principles, CEP/DMF development and API capacity aim to reduce sourcing risk and improve gross margins, while management expects maintenance capex only going forward after significant FY26 capex spend that completed oncology readiness.
Pharmaceuticals & Biotechnology
Pharmaceuticals
2,625 Cr
Low Risk
72.7
37.5
1.2
8.1
1,211.00
333.50
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q1 FY27
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q2 FY23
Discovery themes featuring this stockSakar Healthcare Ltd (SAKAR) is currently trading at 1,179.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sakar Healthcare Limited is an India‑based integrated pharmaceutical manufacturer and CDMO offering API‑to‑FDF capabilities across oral solids, sterile injectables (liquids and lyophilised), oral liquids and oncology formulations, operating EU‑GMP and WHO‑GMP certified facilities and supplying global partners and own‑brand exports to 60+ countries. Sakar has deliberately repositioned toward oncology as a value driver: the Bavla facility is EU‑GMP approved, vertically integrates API and finished dosage manufacturing, and currently lists 55 oncology molecules developed with 32 dossiers ready for launch and eleven marketing authorisations granted, signalling a step‑change in product complexity and margin profile. Q3FY26 displayed a sharp operational inflection: consolidated revenue rose 62% YoY to INR 70.34 crore, EBITDA grew 58% to INR 18.59 crore with 26% margins, and PAT more than doubled to INR 10.25 crore, reflecting improved mix, higher own‑brand exports and early commercialisation of oncology dossiers contributing to near‑term profitability expansion. Commercial traction is supported by deep industry partnerships and technology transfers: Sakar disclosed inclusion as a manufacturing source for Accord/Intas Imatinib supplies, ten tech‑transfer products in process, longstanding client relationships with major Indian multinationals and a shift to own‑brand exports now contributing roughly 70% of revenues, improving margin resilience. Sakar emphasizes sustainable process technology and backward integration: investments in flow chemistry, green chemistry principles, CEP/DMF development and API capacity aim to reduce sourcing risk and improve gross margins, while management expects maintenance capex only going forward after significant FY26 capex spend that completed oncology readiness.
Over the past 52 weeks, Sakar Healthcare Ltd has traded between a low of ₹333.50 and a high of ₹1,211.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sakar Healthcare Ltd has a market capitalization of approximately 2,625.04. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sakar Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 72.74 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,625.04 Cr, Sakar Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sakar Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sakar Healthcare Ltd is 72.74. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
228.95 | 2,788 Cr | -82.48 | 2.33 | 0.27 | 3.03 | 3.56 | -1.43 | ||
170.45 | 2,672 Cr | 165.37 | 0.40 | 0.00 | 1.46 | 2.66 | 0.14 | ||
1179.80 | 2,625 Cr | 72.74 | 8.09 | 0.00 | 9.40 | 12.54 | 7.50 | ||
56.00 | 2,467 Cr | 68.44 | 24.62 | 0.02 | 24.55 | 31.50 | 28.93 | ||
248.00 | 2,302 Cr | 742.45 | 2.45 | 0.08 | -10.13 | 0.77 | 0.12 | ||
1108.00 | 2,285 Cr | 34.38 | 3.93 | 0.57 | 11.44 | 14.90 | 7.32 | ||
2055.20 | 2,278 Cr | 49.23 | 9.27 | 0.00 | 16.95 | 17.46 | 9.33 | ||
| Median: 7 Co. | — | 248.00 | 2,467 Cr | 68.44 | 3.93 | 0.02 | 9.40 | 12.54 | 7.32 |
